Company Presentation August 2024 FORWARD-LOOKING STATEMENTS Certain statements contained in this presentation, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our timeline and planned development of the G4X and other future products; (ii) expected features, capabilities and specifications of the G4X and other future products and service offerings; ...

Core Insights - Singular Genomics Systems, Inc. announced key development milestones for its G4X™ Spatial Sequencer at the AGBT conference, emphasizing its role in advancing precision medicine [1] Group 1: G4X Early Access Program - The G4X Early Access Program is currently active at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback on the platform's real-world potential [2] - Early access sites have reported high throughput and quality data generation across multiple sample types, aligning with the needs of the spatial biology field [3] - Singular plans to expand the early access program to additional sites in Q2, with pre-orders for the G4X now open and initial shipments expected in June 2025 [3] Group 2: Multiomic Performance and 3D Reconstruction - Singular Genomics showcased the G4X platform's robust integrated multiomic performance, demonstrating high sensitivity, specificity, and reproducibility in various cancer panels [5] - Advanced 3D multi-omic reconstruction was presented, utilizing data from 10 serial renal cell carcinoma FFPE sections, encompassing over 6.2 million cells and 438 million transcripts from a single flow cell [6] - The G4X system's ability to measure transcripts, proteins, and fH&E within the same sample enhances reproducibility and facilitates advanced spatial analyses [7] Group 3: Direct Sequencing and Data Availability - Singular advanced its Direct-Seq technology, enabling accurate sequencing of T- and B-cell receptors in tissue samples [8] - Researchers can access raw and demo datasets from Singular's multi-tissue performance studies to validate the platform's capabilities [9] Group 4: Company Overview - Singular Genomics is focused on developing next-generation sequencing and multiomics technologies, with the G4X™ Spatial Sequencer leveraging proprietary sequencing technology for in situ readouts [10]

Core Insights - Singular Genomics Systems, Inc. announced key development milestones for its G4X™ Spatial Sequencer at the AGBT conference, emphasizing its role in advancing precision medicine [1] G4X Early Access Program - The G4X Early Access Program is currently active at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback on the platform's real-world potential [2] - Feedback from early access sites highlights the G4X's high throughput and ability to generate high-quality data across multiple sample types, aligning with the needs of the spatial biology field [3] Performance and Capabilities - The G4X platform demonstrated robust integrated multiomic performance, showing high sensitivity, specificity, and reproducibility in FFPE samples across various cancer types [5] - Advanced 3D multi-omic reconstruction was showcased, analyzing over 6.2 million cells and 438 million transcripts from a single G4X flow cell [6] - The system's ability to measure transcripts, proteins, and fH&E within the same sample enhances reproducibility and facilitates advanced spatial analyses of immune-tumor interactions [7] Technological Advancements - Singular advanced its Direct-Seq technology, enabling accurate sequencing of T- and B-cell receptors in FFPE tonsil samples [8] - Researchers can access raw and demo datasets from multi-tissue performance studies to validate the platform's capabilities [9] Company Overview - Singular Genomics develops next-generation sequencing and multiomics technologies, with the G4® Sequencing Platform already commercially available and the G4X™ Spatial Sequencer currently in development [10]

Core Viewpoint - Singular Genomics Systems, Inc. has been acquired by an affiliate of Deerfield Management Company, L.P., transitioning to a private company to enhance its business strategy and operational flexibility [1][3]. Company Overview - Singular Genomics is a life science technology company focused on next-generation sequencing (NGS) and multiomics technologies, with products like the G4 Sequencing Platform and the upcoming G4X™ Spatial Sequencer [6]. - The G4 Sequencing Platform is designed for fast and accurate genomic sequencing, while the G4X™ Spatial Sequencer aims to provide in situ readouts for various biological analyses [6]. Acquisition Details - The acquisition agreement was signed on December 23, 2024, with Deerfield agreeing to purchase all outstanding shares of Singular Genomics common stock at $20.00 per share in cash [2]. - The transaction was approved by Singular Genomics' shareholders on February 19, 2025, and officially closed shortly thereafter [3]. - Following the acquisition, Singular Genomics' common stock has been suspended from trading on Nasdaq, and the company has requested delisting [3]. Leadership Changes - Josh Stahl has been appointed as the new Chief Executive Officer of Singular Genomics and will join the Board of Directors, alongside Jason Myers [4]. - Drew Spaventa, the co-founder and former CEO, will remain on the Board and take on the role of special advisor to the CEO [4]. Strategic Direction - Deerfield's involvement is expected to support Singular Genomics in advancing its technology and business direction, enhancing its capabilities in providing critical sequencing and multiomics information to healthcare professionals [5].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board and management of Singular Genomics Systems, Inc. in relation to a merger agreement with Deerfield Management Company, L.P. [1][2] Group 1: Investigation Details - The investigation aims to determine if Singular Genomics' board acted in the best interest of shareholders during the merger process [2] - Singular Genomics announced a definitive merger agreement on December 23, 2024, where it will be acquired for $20.00 per share in an all-cash transaction [2] Group 2: Legal Representation - The Schall Law Firm offers free consultations to discuss shareholder rights and potential claims related to the investigation [3] - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3]

Core Viewpoint - The Schall Law Firm is inviting investors who have incurred losses to participate in an inquiry regarding Singular Genomics Systems, Inc. for potential securities fraud [1] Group 1 - The inquiry is focused on potential securities fraud involving Singular Genomics Systems, Inc. [1] - Investors who have suffered losses are encouraged to join the investigation [1] - The Schall Law Firm is known for its focus on securities fraud cases [1]

Legal Investigation - Singular Genomics Systems Inc is under investigation for potential securities law violations [1] - The Schall Law Firm is encouraging affected shareholders to contact them regarding the investigation [1]

Core Viewpoint - Singular Genomics has entered into a definitive merger agreement with an affiliate of Deerfield Management Company, L.P., for an all-cash transaction valued at $20.00 per share, representing a 254% premium over the last closing share price prior to the initial acquisition proposal [4][5]. Company Overview - Singular Genomics is a life science technology company specializing in next-generation sequencing (NGS) and multiomics technologies, with products like the G4® Sequencing Platform and the upcoming G4X™ Spatial Sequencer [10]. - The company aims to empower researchers and clinicians to advance science and medicine [10]. Transaction Details - The merger agreement was approved by the Singular Genomics Board of Directors after a special committee of independent directors evaluated strategic alternatives [6]. - The transaction is expected to close in the first half of 2025, pending customary closing conditions, including stockholder approval [8]. - Upon completion, Singular Genomics will transition to a private company, which is anticipated to provide greater flexibility in advancing its business strategy [7]. Financial Aspects - The acquisition price of $20.00 per share indicates a significant premium, enhancing the attractiveness of the offer to Singular Genomics' stockholders [5]. - Financial advisors for the transaction include TD Securities and Houlihan Lokey, while legal counsel is provided by Gunderson Dettmer, LLP [9].

Financial Performance and Losses - The company incurred a net loss of $63.1 million and used $61.5 million of cash in operations during the nine months ended September 30, 2024[60] - As of September 30, 2024, the company had an accumulated deficit of $400.7 million[60] - Revenue for the three months ended September 30, 2024 decreased by $56,000 (12%) to $406,000 compared to $462,000 in the same period in 2023[65] - Gross margin for the three months ended September 30, 2024 was $(301,000), a 363% decrease compared to $(65,000) in the same period in 2023[65] - Revenue for the nine months ended September 30, 2024 decreased by $244,000 (13%) to $1.6 million compared to $1.8 million in the same period in 2023[65] - Gross margin for the nine months ended September 30, 2024 was $(897,000), a 788% decrease compared to $(101,000) in the same period in 2023[65] - The company recognized $0.4 million of revenue for sales of consumables and services and no revenue for sales of instruments during the three months ended September 30, 2024[66] - The company recognized $1.6 million of revenue, consisting of $0.5 million for instrument sales and $1.1 million for sales of consumables and services during the nine months ended September 30, 2024[68] - The company expects to continue incurring significant losses and does not anticipate positive cash flows from operations in the foreseeable future[81] Cash Flow and Financing Activities - The company raised aggregate net proceeds of approximately $447.4 million, including $237.2 million from its IPO and $130.5 million from convertible promissory notes[60] - The company had cash, cash equivalents, and short-term investments of $113.8 million as of September 30, 2024[60] - Cash provided by investing activities was $97.8 million for the nine months ended September 30, 2024, primarily from proceeds of maturities and sales of available-for-sale securities[86] - Cash used in operating activities was $61.5 million for the nine months ended September 30, 2024, driven by a net loss of $63.1 million and changes in working capital[85] - Cash provided by financing activities was less than $0.1 million for the nine months ended September 30, 2024, primarily from employee stock purchase plan proceeds[87] - The company has a shelf registration statement allowing it to offer up to $250 million of securities, with a sales agreement for up to $100 million of common stock, subject to limitations[82] Product Development and Commercialization - The G4 Sequencing Platform was commercially launched in December 2021, with revenue recognition starting in Q4 2022[59] - The G4X Spatial Sequencer is expected to offer up to 40 cm² of flexible imaging area and single-day run times, with initial customer delivery planned by the end of 2024[59] - The company expects operating expenses to increase in the longer term due to continued development of the G4X and related products, as well as investments in commercial infrastructure[61] Expenses and Cost Management - Research and development expense decreased by $1.7 million (15%) for the three months ended September 30, 2024 compared to the same period in 2023[71] - Selling, general and administrative expenses decreased by $5.1 million (38%) for the three months ended September 30, 2024 compared to the same period in 2023[65] - Research and development expense decreased by $4.3 million (12%) for the nine months ended September 30, 2024 compared to the same period in 2023[72] - Selling, general and administrative expenses decreased by $10.6 million (14%) for the nine months ended September 30, 2024 compared to the same period in 2023[65] - Selling, general and administrative expenses decreased by $5.1 million (38%) for the three months ended September 30, 2024, compared to the same period in 2023, primarily due to reduced headcount and a $1.6 million gain from lease modification[76] - Selling, general and administrative expenses decreased by $6.3 million (15%) for the nine months ended September 30, 2024, compared to the same period in 2023, driven by reduced employee compensation and impairment expenses[77] Interest and Investment Income - Interest income decreased by $0.9 million (37%) for the three months ended September 30, 2024, and by $1.3 million (19%) for the nine months ended September 30, 2024, due to reduced cash available for investments[79][80] Debt and Loan Agreements - The company refinanced its 2019 SVB Loan, entering into a 2021 SVB Loan with a total principal amount of up to $35.5 million, divided into three tranches: $10.5 million (First Tranche), $15.0 million (Second Tranche), and $10.0 million (subject to approval)[89] - The 2021 SVB Loan has an interest rate of 8.75% as of September 30, 2024, with an initial interest-only period of 36 months, and principal payments began in October 2024[89] - The 2022 SVB Loan Amendment extended the drawdown period for the additional tranches totaling $25.0 million from September 30, 2022, to March 31, 2024, but the draw period expired without being utilized[89] - The company is subject to customary covenants under the SVB Loan, with obligations secured by a first priority security interest in substantially all current and future assets, excluding intellectual property[89] Royalties and Licensing Agreements - Under the Columbia License Agreement, the company is required to pay royalties ranging from low to mid-single digits on net sales of Patent Products and low single-digit royalty rates on Other Products[62] Market and Macroeconomic Risks - The company faces risks from macroeconomic factors, including downward market pressure, extreme volatility, and disruptions in capital and credit markets[63] - There were no substantial changes to the company's market risks during the quarter ended September 30, 2024, compared to the disclosures in the Annual Report for the year ended December 31, 2023[96] Capital Obligations and Lease Commitments - The company has capital obligations including minimum lease payments of $1.4 million for the remainder of 2024, $4.8 million in 2025, and $68.3 million thereafter, along with SVB Loan payments[81] Regulatory and Reporting Status - The company remains an "emerging growth company" under the JOBS Act, with exemptions from certain reporting requirements until the earliest of: $1.235 billion in annual gross revenue, $700 million in equity securities held by non-affiliates, $1.0 billion in non-convertible debt issuance, or December 31, 2026[94] - The company has elected to delay the adoption of new or revised accounting standards until they apply to private companies, as permitted under the JOBS Act[94]

[Overall Performance and Corporate Updates](index=1&type=section&id=Singular%20Genomics%20Reports%20Recent%20Updates%20and%20Third%20Quarter%202024%20Financial%20Results) Singular Genomics achieved significant Q3 2024 milestones, including G4X instrument shipment and new data presentations, reinforcing product line progress [Recent Corporate Achievements](index=1&type=section&id=Recent%20Updates) Singular Genomics achieved key Q3 2024 milestones, including G4X instrument shipment and new data presentations, reinforcing product line progress - Shipped the first **G4X Early Access instrument**, a key milestone in its product development pipeline[3](index=3&type=chunk) - Presented new data sets at the **Society for Immunotherapy of Cancer (SITC) conference**, highlighting the G4X's performance on various tissue types and its capability for single-cell immune repertoire profiling[3](index=3&type=chunk) - Shipped **two G4 systems** in the third quarter of 2024[3](index=3&type=chunk) - The CEO expressed confidence in the **G4X spatial sequencer's potential** to deliver high-throughput spatial sequencing and multiomics with superior value, citing positive interest from the Spatial Technology Access Services project funnel[2](index=2&type=chunk) [Financial Performance](index=1&type=section&id=Third%20Quarter%202024%20Financial%20Results) Singular Genomics reported Q3 2024 revenue of $0.4 million, a net loss of $16.8 million, and reduced operating expenses [Q3 2024 Financial Highlights](index=1&type=section&id=Third%20Quarter%202024%20Financial%20Results) Singular Genomics reported Q3 2024 revenue of $0.4M, net loss of $16.8M, reduced expenses, and $113.8M cash Q3 2024 Financial Summary (in millions USD, except per share) | Financial Metric | Q3 2024 | Q3 2023 | | :--- | :--- | :--- | | Revenue | $0.4 | $0.46 | | Gross Profit | -$0.3 | -$0.1 | | Operating Expenses | $17.8 | $24.5 | | Net Loss | $16.8 | $22.4 | | Loss Per Share | $6.72 | $9.25 | - Cash, cash equivalents, and short-term investments totaled **$113.8 million** as of September 30, 2024[4](index=4&type=chunk) - Gross margin was negatively impacted by reagent rental and other non-capital purchase instrument placements, as well as higher support costs for system placements[4](index=4&type=chunk) - The company will not host a conference call due to ongoing discussions related to a potential strategic transaction[4](index=4&type=chunk) [Consolidated Statements of Operations](index=2&type=section&id=Singular%20Genomics%20Systems%2C%20Inc.%20Statements%20of%20Operations) Q3 2024 revenue decreased to $0.41 million, with reduced operating expenses leading to a net loss of $16.80 million Consolidated Statements of Operations (in thousands USD) | Metric | Three Months Ended Sep 30, 2024 | Three Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | **Revenue** | **$406** | **$462** | **$1,586** | **$1,830** | | Gross margin | $(301) | $(65) | $(897) | $(101) | | Research and development | $9,568 | $11,220 | $31,790 | $36,074 | | Selling, general and administrative | $8,202 | $13,254 | $35,036 | $41,345 | | **Total operating expenses** | **$17,770** | **$24,474** | **$66,826** | **$77,419** | | Loss from operations | $(18,071) | $(24,539) | $(67,723) | $(77,520) | | **Net loss** | **$(16,795)** | **$(22,360)** | **$(63,073)** | **$(71,571)** | [Consolidated Balance Sheets](index=4&type=section&id=Singular%20Genomics%20Systems%2C%20Inc.%20Balance%20Sheets) Total assets decreased to $186.6 million by Q3 2024, driven by lower short-term investments, with liabilities also reduced Consolidated Balance Sheets (in thousands USD) | Metric | September 30, 2024 (Unaudited) | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $52,620 | $16,233 | | Short-term investments | $61,213 | $157,708 | | Total current assets | $129,810 | $192,228 | | **Total assets** | **$186,551** | **$265,467** | | **Liabilities and Equity** | | | | Total current liabilities | $17,609 | $18,287 | | **Total liabilities** | **$63,298** | **$86,461** | | **Total stockholders' equity** | **$123,253** | **$179,006** | | Total liabilities and stockholders' equity | $186,551 | $265,467 |